FI111224B - Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi - Google Patents

Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi Download PDF

Info

Publication number
FI111224B
FI111224B FI946104A FI946104A FI111224B FI 111224 B FI111224 B FI 111224B FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A FI 111224 B FI111224 B FI 111224B
Authority
FI
Finland
Prior art keywords
preparation
att
immunoglobulin
förfarande enligt
preparatet
Prior art date
Application number
FI946104A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI946104A0 (fi
FI946104A (fi
Inventor
Johann Eibl
Yendra Linnau
Wolfgang Teschner
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI111224(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of FI946104A0 publication Critical patent/FI946104A0/fi
Publication of FI946104A publication Critical patent/FI946104A/fi
Application granted granted Critical
Publication of FI111224B publication Critical patent/FI111224B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI946104A 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi FI111224B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4344824 1993-12-28
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Publications (3)

Publication Number Publication Date
FI946104A0 FI946104A0 (fi) 1994-12-27
FI946104A FI946104A (fi) 1995-06-29
FI111224B true FI111224B (fi) 2003-06-30

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946104A FI111224B (fi) 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi

Country Status (15)

Country Link
US (1) US5608038A (no)
EP (1) EP0661060B1 (no)
JP (1) JP3040678B2 (no)
AT (2) AT407707B (no)
CA (1) CA2138853A1 (no)
CZ (1) CZ284186B6 (no)
DE (2) DE4344824C1 (no)
DK (1) DK0661060T3 (no)
ES (1) ES2158877T3 (no)
FI (1) FI111224B (no)
HR (1) HRP941018B1 (no)
HU (1) HU220766B1 (no)
NO (1) NO315260B1 (no)
RU (1) RU2104713C1 (no)
YU (1) YU77994A (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002030463A2 (en) * 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
RU2442571C2 (ru) * 2004-07-23 2012-02-20 Дженентек, Инк. Кристаллизация антител или их фрагментов
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
TWI532498B (zh) * 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
MX2011009306A (es) * 2009-03-06 2011-10-13 Genentech Inc Formulacion con anticuerpo.
AU2010296017C1 (en) 2009-09-17 2013-09-19 Takeda Pharmaceutical Company Limited Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
WO2011109452A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI)
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN110496099B (zh) 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含粘度降低剂的液体蛋白质制剂
EP3071181B1 (en) 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
MX2017004306A (es) 2014-10-01 2017-12-20 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
FI3334747T3 (fi) 2015-08-13 2023-11-30 Amgen Inc Antigeenia sitovien proteiinien varattu syväsuodatus
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763B1 (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3483784D1 (de) * 1984-07-07 1991-01-31 Woelm Pharma Gmbh & Co Verfahren zur herstellung von gamma-globulin zur intravenoesen anwendung.
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
HU220766B1 (hu) 2002-05-28
EP0661060B1 (de) 2001-05-23
NO315260B1 (no) 2003-08-11
HRP941018A2 (en) 1997-04-30
NO945045L (no) 1995-06-29
NO945045D0 (no) 1994-12-27
CZ328494A3 (en) 1995-07-12
EP0661060A2 (de) 1995-07-05
CA2138853A1 (en) 1995-06-29
ES2158877T3 (es) 2001-09-16
YU77994A (sh) 1997-03-07
CZ284186B6 (cs) 1998-09-16
DE59409761D1 (de) 2001-06-28
AT407707B (de) 2001-05-25
EP0661060A3 (de) 1997-01-15
FI946104A0 (fi) 1994-12-27
DK0661060T3 (da) 2001-07-30
HU9403795D0 (en) 1995-02-28
HRP941018B1 (en) 1999-12-31
JPH07206709A (ja) 1995-08-08
US5608038A (en) 1997-03-04
RU2104713C1 (ru) 1998-02-20
ATA237894A (de) 2000-10-15
ATE201328T1 (de) 2001-06-15
DE4344824C1 (de) 1995-08-31
FI946104A (fi) 1995-06-29
JP3040678B2 (ja) 2000-05-15
HUT70449A (en) 1995-10-30

Similar Documents

Publication Publication Date Title
FI111224B (fi) Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi
AU735411B2 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
US5945098A (en) Stable intravenously-administrable immune globulin preparation
US4396608A (en) Intravenously injectable immune serum globulin
FI112169B (fi) Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi
KR100942399B1 (ko) Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제
JPH09500894A (ja) 安定化された免疫グロブリンの調製物と、その調製方法
AU2004244920B2 (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
ES2382934T3 (es) Procedimiento de estabilización de un crioprecipitado de proteinas plasmáticas destinado a someterse a un tratamiento térmico de inactivación viral
CA1214102A (en) Pharmaceutical preparation containing purified fibronectin
CZ302750B6 (cs) Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku
KR100276155B1 (ko) 화학적으로 변형되지 않은 γ-글로불린 제제
MXPA99004565A (en) Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies
JPH08500601A (ja) 調製済みのアゾセミド（ａｚｏｓｅｍｉｄｅ）注射液
BRPI9715268B1 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção

Legal Events

Date Code Title Description
MA Patent expired